AeroLeads people directory · profile

Sumit Aggarwal Email & Phone Number

President and CEO @ Eloxx Pharmaceuticals | Transformative Change Leader, Innovator and Investor at Eloxx Pharmaceuticals
Location: Greater Boston, United States, United States 10 work roles 2 schools
1 work email found @eloxxpharma.com 3 phones found area 617 LinkedIn matched
✓ Verified Jun 2026 4 data sources Profile completeness 100%

Contact Signals · 1 work email · 3 phones

Work email s****@eloxxpharma.com
Direct phone (617) ***-****
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
President and CEO @ Eloxx Pharmaceuticals | Transformative Change Leader, Innovator and Investor
Location
Greater Boston, United States, United States

Who is Sumit Aggarwal? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Sumit Aggarwal is listed as President and CEO @ Eloxx Pharmaceuticals | Transformative Change Leader, Innovator and Investor at Eloxx Pharmaceuticals, based in Greater Boston, United States, United States. AeroLeads shows a work email signal at eloxxpharma.com, phone signal with area code 617, and a matched LinkedIn profile for Sumit Aggarwal.

Sumit Aggarwal previously worked as President and CEO at Eloxx Pharmaceuticals and President and CEO at Zikani Therapeutics. Sumit Aggarwal holds Mba, Finance And Strategy from Cornell Johnson Graduate School Of Management.

Company email context

Email format at Eloxx Pharmaceuticals

This section adds company-level context without repeating Sumit Aggarwal's masked contact details.

{first}@eloxxpharma.com
86% confidence

AeroLeads found 1 current-domain work email signal for Sumit Aggarwal. Compare company email patterns before reaching out.

Profile bio

About Sumit Aggarwal

I am a seasoned executive with over 25 years of experience in the pharma, biotech, diagnostic, and medical technology sectors. I have a track record of raising over $250 million in public equity, venture, and debt funding, leading business turnarounds, and executing strategic partnerships and acquisitions. I have an MBA in Finance and Strategy from Cornell University, Johnson School, one of the top business schools in the US.Currently, I am the President and CEO of Eloxx Pharmaceuticals, a biotech company developing novel therapies for rare diseases and cancers driven by nonsense mutations. I joined Eloxx in April 2021, after engineering the sale of Zikani Therapeutics, a Harvard spin-off that I led as President and CEO, generating a 3X return for Series A-1 investors. At Eloxx, I am focused on advancing our pipeline, expanding our global footprint, and delivering value to our shareholders, patients, and partners. My mission is to leverage my expertise in rare diseases, oncology, genomic tools, diagnostics, and devices, and my passion for innovation, to bring life-changing treatments to the market.

Listed skills include Strategy, Private Equity, Valuation, Due Diligence, and 20 others.

Current workplace

Sumit Aggarwal's current company

Company context helps verify the profile and gives searchers a useful next step.

Eloxx Pharmaceuticals
Eloxx Pharmaceuticals
President and CEO @ Eloxx Pharmaceuticals | Transformative Change Leader, Innovator and Investor
AeroLeads page
10 roles · 33 years

Sumit Aggarwal work experience

A career timeline built from the work history available for this profile.

President And Ceo

Zikani Therapeutics

Venture backed Harvard spin-off developing novel macrocyclic ribosome modulators for treating rare mutationally driven inherited diseases and cancers. Engineered a sale to Eloxx Pharmaceuticals generating a 3X return for Series A-1 investorsAsked by investors to takeover as President and CEO in March 2019 with a charter to recommend and implement a.

Mar 2019 - Apr 2021

Chief Financial Officer And Chief Business Officer

Zikani Therapeutics

Initially recruited as the CFO and Chief Business Officer to raise a Series B for the now legacy gram-negative antibiotic company (Macrolide) with only 6 months of cash remaining. Released $8M note tranche in Q4 2018 from all five original investors to extend cash runway to Dec 2019. Evaluated venture debt funding options, reduced cash burn and improved.

Sep 2018 - Dec 2019

Acting President And Chief Financial Officer

Progenity, Inc.
  • $200M+ private genetic services company (500+ employees) offering proprietary pre-natal genetic testing services to OB/GYN with a direct to physician sales force of 200.Recruited by the Executive Chairman and former.
  • Exceeded Revenue growth goals by 3% and 10% respectively in 2016 and 2017 exiting 2017 with $235M in revenues
  • Exceeded EBITDA goals by $24 million and $28million in 2016 and 2017 with highest ever EBITDA margins of >20%
May 2015 - Sep 2018

Senior Healthcare Analyst And Portfolio Manager

New York, NY, US

Managed a new Long/short sleeve of investments in Medical devices, genetic tools, diagnostic services and healthcare payers and providers.Applied unique approach to analyzing key growth inflection points. Top investments generated 3x+ returns

Oct 2013 - Mar 2015

Equity Analyst And Portfolio Manager

Managed market neutral global life science tools, diagnostic products and services and medical technology fund. Evalauted and invested in public and private companies. Senior analyst on Large Pharma and biotech team

May 2007 - Sep 2012

Vice President And Senior Healthcare Analyst

Hartford Investment Managent Company

Founding member of start-up investment venture. Grew assets to $680million. Manage investments in publicly traded global healthcare companies and Indian Equities

Jan 2006 - May 2007

Associate Principal

US

Leader in firm’s global healthcare practice. Served clients in the US, Europe, India and Japan. Advised across range of areas including commercial strategies, product launches, business building, M&A, capital markets. Worked in the New York and London offices and consulted with clients in the North America, Europe, India and Japan

Jul 1998 - Dec 2005

Lead Process Consultant

Led 5-member design team building new chemical plant for private Indian chemical company

1994 - 1996 ~2 yrs
2 education records

Sumit Aggarwal education

Mba, Finance And Strategy

Cornell Johnson Graduate School Of Management

Bachelor Of Technology - Btech, Chemical Engineering

Indian Institute Of Technology, Kharagpur
FAQ

Frequently asked questions about Sumit Aggarwal

Quick answers generated from the profile data available on this page.

What company does Sumit Aggarwal work for?

Sumit Aggarwal works for Eloxx Pharmaceuticals.

What is Sumit Aggarwal's role at Eloxx Pharmaceuticals?

Sumit Aggarwal is listed as President and CEO @ Eloxx Pharmaceuticals | Transformative Change Leader, Innovator and Investor at Eloxx Pharmaceuticals.

What is Sumit Aggarwal's email address?

AeroLeads has found 1 work email signal at @eloxxpharma.com for Sumit Aggarwal at Eloxx Pharmaceuticals.

What is Sumit Aggarwal's phone number?

AeroLeads has found 3 phone signal(s) with area code 617 for Sumit Aggarwal at Eloxx Pharmaceuticals.

Where is Sumit Aggarwal based?

Sumit Aggarwal is based in Greater Boston, United States, United States while working with Eloxx Pharmaceuticals.

What companies has Sumit Aggarwal worked for?

Sumit Aggarwal has worked for Eloxx Pharmaceuticals, Zikani Therapeutics, Progenity, Inc., Millennium Partners, and Adage Capital Management.

How can I contact Sumit Aggarwal?

You can use AeroLeads to view verified contact signals for Sumit Aggarwal at Eloxx Pharmaceuticals, including work email, phone, and LinkedIn data when available.

What schools did Sumit Aggarwal attend?

Sumit Aggarwal holds Mba, Finance And Strategy from Cornell Johnson Graduate School Of Management.

What skills is Sumit Aggarwal known for?

Sumit Aggarwal is listed with skills including Strategy, Private Equity, Valuation, Due Diligence, Pharmaceutical Industry, Equities, Investments, and Management.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.